Jiangsu Hengrui Pharmaceuticals(600276.SH): SHR-1139 Injection Receives Approval for Clinical Trials of Drugs
Hengrui Medicine Co., Ltd. (600276.SH) announced that its subsidiary, Guangdong Hengrui Medicine Co., Ltd., recently received a notification from the country...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the injection SHR-1139. The clinical trials will be conducted soon.
SHR-1139 injection is a biopharmaceutical developed independently by the company, expected to synergistically enhance the treatment of ulcerative colitis by inhibiting inflammatory reactions and maintaining the epithelial barrier. It has been found that there are currently no similar drugs approved for market in China or overseas. As of now, the total investment in the SHR-1139 injection project has reached approximately 71.28 million yuan.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
